The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma

The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma

Meningioma is the most common primary intracranial tumour, and surgical resection is the main therapeutic option. Merlin is a tumour suppressor protein that is frequently mutated in meningioma. The activity of the E3 ubiquitin ligase complex, CRL4-DCAF1, and the Raf/MEK/ERK scaffold protein Kinase s...

Full description

Bibliographic Details
Main Authors: Jade Lyons Rimmer, Emanuela Ercolano, Daniele Baiz, Mahindra Makhija, Allison Berger, Todd Sells, Steve Stroud, David Hilton, Claire L. Adams, C Oliver Hanemann
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Cancers
Subjects:
Merlin
meningioma
CRL4-DCAF1
KSR1
Raf/MEK/ERK
Online Access:https://www.mdpi.com/2072-6694/12/7/1744

Internet

https://www.mdpi.com/2072-6694/12/7/1744

Similar Items